Entera Bio Ltd
ENTX2.060USD
+0.110+5.64%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
93.57MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Entera Bio Ltd Unternehmen
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Unternehmensinformationen
BörsenkürzelENTX
Name des UnternehmensEntera Bio Ltd
IPO-datumJun 28, 2018
CEOMs. Miranda Jayne Toledano
Anzahl der mitarbeiter18
WertpapierartOrdinary Share
GeschäftsjahresendeJun 28
AddresseHadassah / Jerusalem Bio
StadtJERUSALEM
BörseNASDAQ Capital Market Consolidated
LandIsrael
Postleitzahl9112002
Telefon97225327151
Websitehttps://enterabio.com/
BörsenkürzelENTX
IPO-datumJun 28, 2018
CEOMs. Miranda Jayne Toledano
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
324.96K
--
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
291.45K
+163.16%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
134.73K
--
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
64.65K
--
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
47.26K
--
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
46.94K
--
Mr. Ron Abraham Mayron
Mr. Ron Abraham Mayron
Independent Director
Independent Director
--
--
Ms. Dana Yaacov-Garbeli
Ms. Dana Yaacov-Garbeli
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Director
Director
--
--
Dr. Hillel Galitzer
Dr. Hillel Galitzer
Chief Operating Officer
Chief Operating Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
324.96K
--
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
291.45K
+163.16%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
134.73K
--
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
64.65K
--
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
47.26K
--
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
46.94K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, Jul 17
Aktualisiert: Thu, Jul 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Knoll Capital Management, LLC
12.94%
OPKO Health Inc
8.50%
D.N.A Biomedical Solutions, Ltd.
8.21%
Point72 Asset Management, L.P.
5.93%
Centillion Fund Inc
5.27%
Other
59.14%
Aktionäre
Aktionäre
Anteil
Knoll Capital Management, LLC
12.94%
OPKO Health Inc
8.50%
D.N.A Biomedical Solutions, Ltd.
8.21%
Point72 Asset Management, L.P.
5.93%
Centillion Fund Inc
5.27%
Other
59.14%
Aktionärstypen
Aktionäre
Anteil
Corporation
21.99%
Hedge Fund
21.33%
Individual Investor
2.44%
Investment Advisor
0.70%
Research Firm
0.07%
Investment Advisor/Hedge Fund
0.05%
Venture Capital
0.02%
Other
53.41%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
44
20.97M
46.14%
-173.92K
2025Q1
48
20.87M
47.30%
+2.99M
2024Q4
45
14.59M
39.63%
+276.18K
2024Q3
44
12.66M
34.61%
+129.89K
2024Q2
43
12.40M
34.23%
+1.30M
2024Q1
39
11.33M
31.94%
+147.25K
2023Q4
38
10.84M
34.31%
+2.50M
2023Q3
40
9.31M
32.31%
-70.93K
2023Q2
42
9.22M
32.01%
-186.20K
2023Q1
42
9.45M
32.81%
-129.12K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Knoll Capital Management, LLC
5.88M
12.94%
--
--
Mar 31, 2025
OPKO Health Inc
3.87M
8.5%
+180.00K
+4.88%
May 08, 2025
D.N.A Biomedical Solutions, Ltd.
3.73M
8.21%
--
--
May 08, 2025
Point72 Asset Management, L.P.
2.70M
5.93%
-4.32K
-0.16%
Mar 31, 2025
Centillion Fund Inc
2.40M
5.27%
--
--
May 08, 2025
Schonfeld Strategic Advisors LLC
599.16K
1.32%
-33.16K
-5.24%
Mar 31, 2025
Parkman Healthcare Partners LLC
439.63K
0.97%
+25.90K
+6.26%
Mar 31, 2025
Lieberman (Gerald M)
324.96K
0.71%
--
--
May 08, 2025
Toledano (Miranda Jayne)
110.75K
0.24%
--
--
May 08, 2025
Northern Trust Global Investments Limited
198.83K
0.44%
-13.65K
-6.42%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
